Cybrexa Inc - also dba CYBREXA Therapeutics, Inc.,- is working on next generation of cancer therapeutics that specifically target tumors and their underlying biology. The firm's approach - designated Cybrexa Alphalex⢠leverages the low-pH tumor microenvironment for selective targeting. Essentaily, the approach selectively differentiates between tumor and healthy tissue without dependence on any cellular factors (including antigens) in any solid tumor. The approach delivers therapeutics intracellularly providing deep tissue penetration that is compatible with most classes of small molecule anticancer agents withthe added benefit of enabling simple and scalable manufacturing
